Abbott lauded a nearly 20% organic increase in its overall diabetes care sales — with 27% growth in the United States — as the company reported strong earnings results for first-quarter 2025.
“Over the course of our more than 135 years in business, Abbott (NYSE: ABT) has proven time and again that we can adeptly navigate through periods of uncertainty,” the company said in an April 16 press release. “As you can see in our first-quarter 2025 results, our diversified business model allowed us to deliver strong, sustainable growth and reaffirm our full-year guidance — even in a rapidly evolving environment.”
Abbott’s medical devices segment — which includes diabetes care — had a sales increase of almost 13% on an organic basis, “marking yet another quarter of double-digit growth,” the company said.
The company’s nutrition sales were up almost 7% on an organic basis, a boost led by nearly 9% organic growth in Abbott’s adult nutrition segment. Global sales for Abbott’s pediatric nutrition products were up 4.9% on an organic basis.
In the midst of strong earnings results, Abbott reported building for the future. “We also continue to strengthen our new product pipeline and broaden the impact of our life-saving technologies,” the company said, adding that $500 million worth of manufacturing and R&D investments in Illinois and Texas “are projected to go live by the end of 2025.”
Worldwide sales for Q1 were $10.4 billion, up 6.9% on an organic basis. “Adjusted diluted earnings per share (EPS) came in at $1.09, beating Street consensus of $1.07 and above the midpoint of our guidance (GAAP [generally accepted accounting principles] diluted EPS was $0.76),” Abbott reported.
“Once again, Abbott’s diversified business model delivered top-tier sales and EPS growth,” said Robert B. Ford, Abbott’s chairman and CEO. “It is this diversification and execution that allows Abbott to navigate through periods of uncertainty and continually deliver sustainable growth.”
